Zhu Panyong, Lv Pin, Zhang Yazhou, Liao Rongqiang, Liu Jing, Guo Rong, Chen Xuan, Liao Xiali, Gao Chuanzhu, Zhang Kun, Yang Ming, Yang Bo
Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China.
Industrial Crop Research Institute, Yunnan Academy of Agricultural Sciences, Kunming, China.
Front Chem. 2021 Nov 8;9:754832. doi: 10.3389/fchem.2021.754832. eCollection 2021.
Cannabidiol (CBD) is one specific kind of the cannabinoid in with a wide range of pharmacological activities. However, the poor water solubility and specificity of CBD limits its application in pharmaceutical field. For solving these problems, in this work, we successfully prepared a targeted carrier by grafting biotin (BIO) onto ethylenediamine-β-Cyclodextrin (EN-CD) in a single step to generate a functionalized supramolecule, named BIO-CD. Subsequently, an amantadine-conjugated cannabinoids (AD-CBD) was prepared and self-assembled with the BIO-CD. A series of methods were used to characterize the inclusion behavior and physicochemical properties of AD-CBD and BIO-CD. The results showed that AD-CBD entered the cavity of BIO-CD and formed a 1:1 host-guest inclusion complex. MTT assay and confocal laser scanning microscopy (CLSM) revealed that the targeting effect and anticancer activity of AD-CBD/BIO-CD inclusion complex against three human cancer cell lines were higher than BIO-CD, AD-CBD and free CBD. Moreover, the inclusion complex could release drugs under weakly acidic conditions. These results demonstrated that AD-CBD/BIO-CD inclusion complex possess excellent targeted and anticancer activity, which is hopeful to be applied in clinic as a new therapeutic approach.
大麻二酚(CBD)是大麻素中的一种特定类型,具有广泛的药理活性。然而,CBD较差的水溶性和特异性限制了其在制药领域的应用。为了解决这些问题,在本研究中,我们通过一步法将生物素(BIO)接枝到乙二胺-β-环糊精(EN-CD)上成功制备了一种靶向载体,生成了一种功能化超分子,命名为BIO-CD。随后,制备了金刚烷共轭大麻素(AD-CBD)并与BIO-CD自组装。使用一系列方法表征了AD-CBD和BIO-CD的包合行为和物理化学性质。结果表明,AD-CBD进入了BIO-CD的空腔并形成了1:1的主客体包合物。MTT法和共聚焦激光扫描显微镜(CLSM)显示,AD-CBD/BIO-CD包合物对三种人类癌细胞系的靶向作用和抗癌活性高于BIO-CD、AD-CBD和游离CBD。此外,该包合物可在弱酸性条件下释放药物。这些结果表明,AD-CBD/BIO-CD包合物具有优异的靶向性和抗癌活性,有望作为一种新的治疗方法应用于临床。